Phathom Pharmaceuticals, Inc.: shareholders and insiders

PHATNASDAQHealthcare · Pharmaceutical Preparations

Price

$5.30

November 18, 2026Market cap $418M

What Ploutos Investor adds for Phathom Pharmaceuticals

Part of Ploutos Investor, €9.99 a month

See the plans
  • The full history: 4 fiscal years, from 2022
  • The estimated fair value, with its range and its certainty
  • The full analysis, 18 a month
  • More questions to the chat on its filings
  • Excel with every year
  • An email when it reports, changes its dividend or an officer buys

Sign in with a free account to see the last 5 fiscal years.

Notes on these figures

  • The interest the company pays is far more than the debt we can read would cost, so part of its borrowing is missing from the figures. We leave out the debt, net cash, enterprise value and the multiples built on them.

Insiders and their shares

Purchases and sales by officers and directors from Nov 19, 2025 to Oct 8, 2026, from their own Form 4 filings.

4 Form 4s

Bought on the market

–

nobody

Sold on the market

–

nobody

From Nov 19, 2025 to Nov 19, 2026, the days the chart shows. Change its range and the figures follow.

How the sales were made, as a share of their value

No sales in the period.

No trades under these filters.

From the Form 4s insiders file with the SEC within two business days of each trade.

Insiders and their shares

Every buy and sale by PHAT's officers and directors from 2019 up to November 18, 2025, 7 more calendar years

Part of Ploutos Investor, €9.99 a month

See the plans

Sign in with a free account to see the last 3 years.

Major holders (over 5%)

Whoever comes to own more than 5% of a class of shares reports it to the SEC on Schedule 13D or 13G. Here is each holder's latest filing.

2 Holders over 5%1 On a 13DNov 10, 2026 Latest filing
  • Frazier Life Sciences Public Fund, L.P.with 11 more persons
    Share of class7.40%
  • BlackRock, Inc.
    Share of class5.50%

What the holders on a 13D state as their purpose

From Item 4 of the filing, in the holder's own words. It is the intention the holder states, not something that happened.

  • Frazier Life Sciences Public Fund, L.P.7.4%From the filing of Nov 4, 2025

    Item 4 is hereby amended to remove references to "FLSPOF" and the "FLSPOF Shares" from the first paragraph.

    From the filing of Nov 4, 2025
Fell to 5% or less (5)

Holders whose latest filing says they hold 5% or less. After it they need not file again, so what they hold today is not known.

  • Invesco Ltd.0.00%Nov 10, 202613G/A
  • Millennium Management LLC4.20%Jul 20, 202613G/A
  • Carlyle Group Inc.4.90%Aug 28, 202513G/A
  • Jennison Associates LLC0.00%Jun 9, 202513G/A
  • Prudential Financial0.00%Jun 6, 202513G/A

From the Schedule 13D and 13G filed with the SEC since Dec 18, 2024, when they became structured data. A holder who has filed nothing since then is not shown here. A 13D is updated within two business days of any material change, a 13G up to 45 days after the quarter of the change, so the shares are those of the filing. The large managers also appear in the 13Fs.

Well-known managers

Which of the about 30 investment managers we track held the shares at the quarter end, and what they changed from the quarter before.

Sep 30, 2026 quarter end
  • Point72 (Cohen)
    In the quarter
  • Millennium Mgmt (Englander)
    In the quarter-16%
  • Citadel Advisors (Griffin)
    In the quarter-52%
  • D.E. Shaw
    In the quarter-28%
  • Renaissance Technologies
    In the quarter-90%
  • AQR Capital
    In the quarter+143%

From the 13Fs managers file with the SEC up to 45 days after each quarter end. They show only long positions on that day, not short sales or what has changed since. No recent 13F: Pershing Square (Ackman), Scion (Burry).

Short interest

How many of the company's shares have been sold borrowed and not yet bought back, twice a month.

On Oct 15, 2026, 12.4% of its shares outstanding were held short, -3.2% since the report before.

Shares held short
9.78M
12.4%
Since the report before10.11M on Sep 30, 2026
-3.2%
6.9
1.41M
More days to cover thanof 4,578 US-listed companies with enough volume
77%
Report date
Oct 15, 2026
  • Oct 31, 2023: Shares held short 4.12M
  • Nov 15, 2023: Shares held short 4.87M
  • Nov 30, 2023: Shares held short 5.50M
  • Dec 15, 2023: Shares held short 6.27M
  • Dec 29, 2023: Shares held short 7.08M
  • Jan 12, 2024: Shares held short 8.19M
  • Jan 31, 2024: Shares held short 8.63M
  • Feb 15, 2024: Shares held short 9.25M
  • Feb 29, 2024: Shares held short 8.67M
  • Mar 15, 2024: Shares held short 10.44M
  • Mar 28, 2024: Shares held short 10.65M
  • Apr 15, 2024: Shares held short 12.03M
  • Apr 30, 2024: Shares held short 11.80M
  • May 15, 2024: Shares held short 12.18M
  • May 31, 2024: Shares held short 12.33M
  • Jun 14, 2024: Shares held short 13.10M
  • Jun 28, 2024: Shares held short 13.40M
  • Jul 15, 2024: Shares held short 13.08M
  • Jul 31, 2024: Shares held short 13.73M
  • Aug 15, 2024: Shares held short 14.25M
  • Aug 30, 2024: Shares held short 15.34M
  • Sep 13, 2024: Shares held short 15.52M
  • Sep 30, 2024: Shares held short 17.22M
  • Oct 15, 2024: Shares held short 17.56M
  • Oct 31, 2024: Shares held short 17.45M
  • Nov 15, 2024: Shares held short 14.66M
  • Nov 29, 2024: Shares held short 14.05M
  • Dec 13, 2024: Shares held short 14.13M
  • Dec 31, 2024: Shares held short 14.95M
  • Jan 15, 2025: Shares held short 14.20M
  • Jan 31, 2025: Shares held short 14.63M
  • Feb 14, 2025: Shares held short 14.86M
  • Feb 28, 2025: Shares held short 13.92M
  • Mar 14, 2025: Shares held short 14.36M
  • Mar 31, 2025: Shares held short 12.91M
  • Apr 15, 2025: Shares held short 11.38M
  • Apr 30, 2025: Shares held short 10.92M
  • May 15, 2025: Shares held short 11.18M
  • May 30, 2025: Shares held short 10.98M
  • Jun 13, 2025: Shares held short 11.04M
  • Jun 30, 2025: Shares held short 8.52M
  • Jul 15, 2025: Shares held short 9.69M
  • Jul 31, 2025: Shares held short 10.09M
  • Aug 15, 2025: Shares held short 12.09M
  • Aug 29, 2025: Shares held short 13.17M
  • Sep 15, 2025: Shares held short 14.00M
  • Sep 30, 2025: Shares held short 13.20M
  • Oct 15, 2025: Shares held short 14.13M
  • Oct 31, 2025: Shares held short 13.57M
  • Nov 14, 2025: Shares held short 13.08M
  • Nov 28, 2025: Shares held short 12.74M
  • Dec 15, 2025: Shares held short 12.68M
  • Dec 31, 2025: Shares held short 10.78M
  • Jan 15, 2026: Shares held short 10.52M
  • Jan 30, 2026: Shares held short 11.40M
  • Feb 13, 2026: Shares held short 11.72M
  • Feb 27, 2026: Shares held short 11.17M
  • Mar 13, 2026: Shares held short 11.66M
  • Mar 31, 2026: Shares held short 10.64M
  • Apr 15, 2026: Shares held short 9.50M
  • Apr 30, 2026: Shares held short 9.74M
  • May 15, 2026: Shares held short 10.29M
  • May 29, 2026: Shares held short 10.35M
  • Jun 15, 2026: Shares held short 11.16M
  • Jun 30, 2026: Shares held short 11.99M
  • Jul 15, 2026: Shares held short 12.12M
  • Jul 31, 2026: Shares held short 13.33M
  • Aug 14, 2026: Shares held short 11.77M
  • Aug 31, 2026: Shares held short 10.82M
  • Sep 15, 2026: Shares held short 10.16M
  • Sep 30, 2026: Shares held short 10.11M
  • Oct 15, 2026: Shares held short 9.78M

As brokers report them to the regulator twice a month, mid-month and at month end, published about eight business days later. A short position is shares sold borrowed and not yet bought back. The share count is the one the company's market value is figured on, from its filings. Days to cover is the shares held short over the average daily volume of the weeks between two reports.

Short sales in daily trading42.8% of the shares in the last 14 sessions' reported trades were short sales.

In the last 14 sessions, 42.8% of the shares in the reported trades were short sales, against 52.4% in the 14 before.

Last 14 sessionsOct 30, 2026 – Nov 18, 2026
42.8%
The 14 beforeOct 12, 2026 – Oct 29, 2026
52.4%
Change
-9.6 pts
Short sales a dayon average, of 664.3K shares
284.5K
More than atof 3,656 US-listed companies, same days
27%
Median of alleight in ten from 34.4% to 63.7%
50.3%
  • Oct 12, 2026: Short sales 60.6%
  • Oct 13, 2026: Short sales 67.5%
  • Oct 14, 2026: Short sales 51%
  • Oct 15, 2026: Short sales 57.5%
  • Oct 16, 2026: Short sales 64.3%
  • Oct 19, 2026: Short sales 67.4%
  • Oct 20, 2026: Short sales 64.7%
  • Oct 21, 2026: Short sales 74.8%
  • Oct 22, 2026: Short sales 57.3%
  • Oct 23, 2026: Short sales 50.4%
  • Oct 26, 2026: Short sales 71.6%
  • Oct 27, 2026: Short sales 40.7%
  • Oct 28, 2026: Short sales 46.9%
  • Oct 29, 2026: Short sales 32.8%
  • Oct 30, 2026: Short sales 33.7%
  • Nov 2, 2026: Short sales 23.9%
  • Nov 3, 2026: Short sales 32.8%
  • Nov 4, 2026: Short sales 31.7%
  • Nov 5, 2026: Short sales 41.7%
  • Nov 6, 2026: Short sales 34.7%
  • Nov 9, 2026: Short sales 78%
  • Nov 10, 2026: Short sales 75.4%
  • Nov 11, 2026: Short sales 38.4%
  • Nov 12, 2026: Short sales 41%
  • Nov 13, 2026: Short sales 44.3%
  • Nov 16, 2026: Short sales 42.1%
  • Nov 17, 2026: Short sales 41.6%
  • Nov 18, 2026: Short sales 46.6%

This is not the number of shares sold short today: it measures short sales within each day's trading, and only trades made off the exchanges. Much of it is market makers, who sell shares they do not have to fill buyers' orders and cover soon after, so for a heavily traded stock the share is often around half.

What the insiders hold

The shares each insider reports holding after their latest trade (Form 4), for those who traded on the market in the last three years.

5.01M Insiders' shares6.36% Of the company
  • Takeda Pharmaceutical Co LtdTenPercentOwner
    Directly3.76M
  • Terrie CurranPresident and Chief Executive
    Directly360.5K
  • Azmi NabulsiChief Operating Officer
    Directly233.4K
  • Sanjeev NarulaChief Financial & Bus. Officer
    Directly215.8K
  • Asit ParikhDirector
    Directly172.6K
  • Molly HendersonCFO and CBO
    Directly89.9K
  • Robert Charles BreedlovePrincipal Accounting Officer
    Directly67.7K
  • James N TopperDirector
    Directly–
  • Frank KarbeDirector
    Directly57.0K

A lower bound: it counts only the 9 officers and directors with a market trade since Nov 20, 2023. Anyone who neither bought nor sold since is not here, whatever they hold. The share is against the share count on the latest 10-K's cover.

The ETFs that hold it

Which of the 345 US equity ETFs we track hold the stock, and at what weight, from the funds' N-PORT filings.

14 ETFs holding it0.13% The largest weight (IHE)
  • IHEiShares U.S. Pharmaceuticals ETF
    Weight in the fund0.13%
  • IWCiShares Micro-Cap ETF
    Weight in the fund0.12%
  • IBBiShares Biotechnology ETF
    Weight in the fund0.05%
  • IWNiShares Russell 2000 Value ETF
    Weight in the fund0.02%
  • IWMiShares Russell 2000 ETF
    Weight in the fund0.02%
  • VTWOVanguard Russell 2000 Index Fund
    Weight in the fund0.01%
  • SCHASchwab U.S. Small-Cap ETF
    Weight in the fund0.01%
  • IWOiShares Russell 2000 Growth ETF
    Weight in the fund0.01%
  • VXFVanguard Extended Market Index Fund
    Weight in the fund0.01%
  • VHTVanguard Health Care Index Fund
    Weight in the fund0.01%

14 of the 345 ETFs we track, not of every ETF on the market. The ten largest weights. Positions as each fund filed them in its latest N-PORT.

Institutional investors by quarter

Every manager that reports positions to the SEC (Form 13F), quarter by quarter: how many hold the stock, how many shares and dollars between them, and who entered, left, added or trimmed during the quarter.

162 Managers, Q2 2026$782M Value of their positions
  • Q3 2025: Managers 134
  • Q4 2025: Managers 173
  • Q1 2026: Managers 175
  • Q2 2026: Managers 162

Institutional investors by quarter

The fund managers holding PHAT, quarter by quarter, from Q4 2019 to Q2 2025, 23 more quarters

Part of Ploutos Investor, €9.99 a month

See the plans

Sign in with a free account to see the last 12 quarters.

Q2 2026: 162 managers held 72.07M shares, worth $782M. During the quarter 22 opened a position, 35 closed one, 57 added and 49 trimmed.

The largest holders, Q2 2026

  • Frazier Life Sciences Management
    In the quarter
  • Medicxi Ventures Management (Jersey)
    In the quarter
  • BlackRock
    In the quarter+11%
  • Invesco
    In the quarter-6.8%
  • Carlyle Group
    In the quarter
  • Millennium Mgmt (Englander)
    In the quarter-16%
  • Vanguard Capital Management
    In the quarter+2.8%
  • GW&K Investment Management
    In the quarter+52%
  • Franklin Resources
    In the quarter+98%
  • NEA Management
    In the quarter

From the SEC's Form 13F data sets, Q3 2025 to Q2 2026: the long positions of every manager with more than $100 million under management, as filed up to 45 days after each quarter end. Short positions and options are not in them. Shares as reported each quarter, not adjusted for splits. The stock is matched by its CUSIP, through the SEC's fails-to-deliver files.

Pay against performance, the say-on-pay vote, buybacks by quarter and trading plans are read for S&P 500 companies only.

The full analysis

What do Phathom Pharmaceuticals's filings show?

Who buys and sells is one part of Phathom Pharmaceuticals's picture. The full Ploutos AI analysis reads everything the company has filed and shows what stands behind it, with a source for every figure.

  • A fair value range built from the filings
  • Earnings quality, debt and red flags
  • Insider and institutional moves
  • The case for and the case against

Questions about PHAT's shareholders

Didn't find what you were looking for?

Ask us
Have PHAT's insiders bought or sold?

From May 27, 2026 to Oct 8, 2026 Phathom Pharmaceuticals's insiders reported no purchase or sale of shares on the market.

Which well-known managers hold PHAT?

6 of the managers we track held the shares on Sep 30, 2026. The largest position was Millennium Mgmt (Englander)'s, worth $37M.

Is every insider transaction a purchase or a sale?

No. Many are part of their pay: share awards, option exercises and shares the company keeps for the tax. Only code P is a purchase with their own money, and code S a sale on the market.

Related pages

The other pages on US stocks, free to read. On the company pages, the last three fiscal years are open to everyone, five with a free account, and every year with Ploutos Investor.

The figures come from the company's SEC filings and the share price, and describe what it has reported. They are not a score or a fair value.